An observational study in Open-Angle Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-06.
Sponsored by Allergan · Observational
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 1,099 is above the median of 103 across 454 observational studies indexed under Glaucoma.
Browse Glaucoma studies →Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients can be either: (a) newly diagnosed and require, in the judgment of the treating physician, one of study agents as first-line treatment, (b) have an insufficiently controlled IOP on their current medication (any but not more than two in combination), and a treatment switch to one of study agents is an acceptable option.
Exclusion Criteria:
bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
1 drop in eye(s) every evening
Also known as: Lumigan®, Xalatan®, Travatan®
Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).
Time frame: Baseline, 1 Year
| Milestone | Lumigan® | Travatan® | Xalatan® |
|---|---|---|---|
| Started | 364 | 370 | 365 |
| Completed | 347 | 356 | 352 |
| Not completed | 17 | 14 | 13 |
| Milestone | Lumigan® | Travatan® | Xalatan® |
|---|---|---|---|
| Started | 347 | 356 | 352 |
| Completed | 160 | 163 | 152 |
| Not completed | 187 | 193 | 200 |
| Milestone | Lumigan® | Travatan® | Xalatan® |
|---|---|---|---|
| Started | 160 | 163 | 152 |
| Completed | 56 | 67 | 50 |
| Not completed | 104 | 96 | 102 |
| Milestone | Lumigan® | Travatan® | Xalatan® |
|---|---|---|---|
| Started | 56 | 67 | 50 |
| Completed | 26 | 35 | 29 |
| Not completed | 30 | 32 | 21 |
Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).
| Millimeters of mercury (mmHg) | Lumigan® | Travatan® | Xalatan® |
|---|---|---|---|
| Baseline | 20.8 ± 5.2 | 20.3 ± 5.0 | 20.6 ± 5.2 |
| Change from Baseline at 1 Year | -4.8 ± 3.3 | -4.3 ± 2.7 | -4.3 ± 2.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumigan® | — | 5/364 (1.4%) | 0/364 (0%) |
| Travatan® | — | 2/370 (0.5%) | 0/370 (0%) |
| Xalatan® | — | 6/365 (1.6%) | 0/365 (0%) |
| Event | Lumigan® | Travatan® | Xalatan® |
|---|---|---|---|
| DeathGeneral disorders | 5/364 | 2/370 | 6/365 |
| Age Continuous(years) | Lumigan® | Travatan® | Xalatan® | Total |
|---|---|---|---|---|
| Median | 65.5 (21 to 97) | 67.0 (32 to 98) | 67.0 (23 to 95) | 67.0 (21 to 98) |
| Sex: Female, Male(Participants) | Lumigan® | Travatan® | Xalatan® | Total |
|---|---|---|---|---|
| Female | 210 | 206 | 201 | 617 |
| Male | 154 | 164 | 164 | 482 |
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergan